These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36997361)

  • 21. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favorable outcomes after heart transplantation in Barth syndrome.
    Li Y; Godown J; Taylor CL; Dipchand AI; Bowen VM; Feingold B
    J Heart Lung Transplant; 2021 Oct; 40(10):1191-1198. PubMed ID: 34330606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
    Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
    Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation.
    Conway J; Manlhiot C; Kirk R; Edwards LB; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2014 Mar; 33(3):241-51. PubMed ID: 24462559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.
    Mehra MR; Uber PA; Scott RL; Park MH
    Transplantation; 2002 Dec; 74(11):1568-73. PubMed ID: 12490790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
    D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
    J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation.
    Almond CS; Hoen H; Rossano JW; Castleberry C; Auerbach SR; Yang L; Lal AK; Everitt MD; Fenton M; Hollander SA; Pahl E; Pruitt E; Rosenthal DN; McElhinney DB; Daly KP; Desai M;
    J Heart Lung Transplant; 2018 Apr; 37(4):441-450. PubMed ID: 28465118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
    Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA
    Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxoplasma Gondii Serostatus in Heart Transplant Recipients: Is It an Independent Prognostic Factor?
    Barge-Caballero E; Barbeito-Caamaño C; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Marzoa-Rivas R; Solla-Buceta M; Estévez-Cid F; Herrera-Noreña JM; Cuenca-Castillo JJ; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1160-1166. PubMed ID: 27597125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of rejection risk following subtherapeutic calcineurin inhibitor levels after pediatric heart transplantation.
    Kerr SM; Jorgensen NW; Hong BJ; Friedland-Little JM; Albers EL; Newland DM; Law YM; Kemna MS
    Pediatr Transplant; 2020 Feb; 24(1):e13616. PubMed ID: 31820529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric recipient survival beyond 15 post-heart transplant years: a single-center experience.
    Copeland H; Razzouk A; Chinnock R; Deming D; Hasaniya N; Bailey L
    Ann Thorac Surg; 2014 Dec; 98(6):2145-50; discussion 2150-1. PubMed ID: 25443019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.
    Jain A; Reyes J; Kashyap R; Rohal S; Abu-Elmagd K; Starzl T; Fung J
    Ann Surg; 1999 Sep; 230(3):441-8; discussion 448-9. PubMed ID: 10493490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of human leukocyte antigen-C and -DQ matching on pediatric heart transplant graft survival.
    Butts RJ; Savage AJ; Nietert PJ; Kavarana M; Moussa O; Burnette AL; Atz AM
    J Heart Lung Transplant; 2014 Dec; 33(12):1282-7. PubMed ID: 25128416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise.
    Kleinmahon JA; Gralla J; Kirk R; Auerbach SR; Henderson HT; Wallis GA; Ramakrishnan K; Singh RK; Caldwell RL; Savage AJ; Everitt MD
    J Heart Lung Transplant; 2019 Mar; 38(3):277-284. PubMed ID: 30638837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medium-term Outcomes in Pediatric Heart Transplant Recipients Managed Using a Steroid Avoidance Immune Suppression Protocol.
    Hartje-Dunn C; Blume ED; Bastardi H; Daly KP; Fynn-Thompson F; Gauvreau K; Singh TP
    Transplantation; 2024 Jan; 108(1):e8-e14. PubMed ID: 37788365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group.
    Rossano JW; Jefferies JL; Pahl E; Naftel DC; Pruitt E; Lupton K; Dreyer WJ; Chinnock R; Boyle G; Mahle WT;
    J Heart Lung Transplant; 2017 Apr; 36(4):427-433. PubMed ID: 28029575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification to determine the impact of induction therapy on survival, rejection and adverse events after pediatric heart transplant: A multi-institutional study.
    Castleberry C; Pruitt E; Ameduri R; Schowengerdt K; Edens E; Hagin N; Kirklin JK; Naftel D; Urschel S
    J Heart Lung Transplant; 2018 Apr; 37(4):458-466. PubMed ID: 28619384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes and management of the heart transplant recipient.
    McCartney SL; Patel C; Del Rio JM
    Best Pract Res Clin Anaesthesiol; 2017 Jun; 31(2):237-248. PubMed ID: 29110796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.